Convergent Therapeutics, Inc. is a clinical-stage biotechnology company located in Cambridge, MA, that has recently raised $90M in Series A funding led by OrbiMed, The Invus Group, and RA Capital Management, L.P. The company's founder, Philip Kantoff, is at the helm of this groundbreaking startup that is set to change the world of cancer therapy. Convergent Therapeutics is developing next-generation targeted radiotherapies to improve outcomes in cancer patients by developing proprietary antibodies that are linked to radionuclides to create a highly potent therapy. These radioantibodies precisely target and kill cancer cells while sparing healthy tissues, resulting in more effective cancer treatment with fewer side effects. 

In particular, their proprietary radiant body, CONV01-α, is a best-in-class therapy targeted to Prostate-Specific Membrane Antigen (PSMA), an antigen expressed on the surface of almost all prostate cancer cells. With a Phase 1 Single Ascending Dose trial that showed promising results in men with metastatic castration-resistant prostate cancer, Convergent Therapeutics is paving the way for a new world of cancer therapy. By pairing highly selective antibodies with a powerful yet precise payload, they offer the ideal combination to treat many types of cancers.